BR0113321A - Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i - Google Patents

Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i

Info

Publication number
BR0113321A
BR0113321A BR0113321-7A BR0113321A BR0113321A BR 0113321 A BR0113321 A BR 0113321A BR 0113321 A BR0113321 A BR 0113321A BR 0113321 A BR0113321 A BR 0113321A
Authority
BR
Brazil
Prior art keywords
angiotensin
antagonists
enzyme inhibitors
antagonist
pharmaceutical combination
Prior art date
Application number
BR0113321-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Peter Boehm
Wolf Thomas Meinicke
Axel Riedel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234234&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0113321(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of BR0113321A publication Critical patent/BR0113321A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
BR0113321-7A 2000-08-22 2001-08-16 Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i BR0113321A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB0020691.2A GB0020691D0 (en) 2000-08-22 2000-08-22 Pharmaceutical combination
DE10108215A DE10108215A1 (de) 2000-08-22 2001-02-20 Pharmazeutische Kombination von Antagonisten von Angiotensin II und Hemmern von Angiotensin II konvertierendem Enzym
PCT/EP2001/009428 WO2002015891A2 (en) 2000-08-22 2001-08-16 Pharmaceutical combination of angiotensin ii antagonists and ace inhibitors
CA002372785A CA2372785A1 (en) 2000-08-22 2002-02-21 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
JP2002093288A JP2003238444A (ja) 2000-08-22 2002-02-21 アンギオテンシンｉｉ拮抗剤及びアンギオテンシンｉ変換酵素阻害剤の医薬組成物

Publications (1)

Publication Number Publication Date
BR0113321A true BR0113321A (pt) 2003-07-15

Family

ID=32234234

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0113321-7A BR0113321A (pt) 2000-08-22 2001-08-16 Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i

Country Status (15)

Country Link
US (1) US20030171415A1 (https=)
EP (1) EP1313468A2 (https=)
JP (1) JP2003238444A (https=)
CN (1) CN1447691A (https=)
AU (1) AU2001295465B2 (https=)
BG (1) BG107558A (https=)
BR (1) BR0113321A (https=)
CA (2) CA2415788A1 (https=)
CZ (1) CZ2003534A3 (https=)
DE (1) DE10108215A1 (https=)
GB (1) GB0020691D0 (https=)
IL (1) IL153937A0 (https=)
NO (1) NO20030761D0 (https=)
SK (1) SK2062003A3 (https=)
WO (1) WO2002015891A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
US20040248968A1 (en) * 2002-02-20 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US9029363B2 (en) * 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
US20050004194A1 (en) * 2003-05-15 2005-01-06 Graves Kurt Chum Use of organic compounds
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
DE102004008804A1 (de) * 2004-02-20 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mehrschichttablette
WO2005097109A1 (en) * 2004-04-01 2005-10-20 Daniel Batlle Methods for achieving a protective ace2 expression level
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
US8080534B2 (en) * 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
EP2684564A1 (en) 2008-04-17 2014-01-15 Sanofi Use of dronedarone for the preparation of a medicament for use in the prevention of cardiovascular hospitalization or in the prevention of atrial fibrillation
EP2116239A1 (en) * 2008-04-29 2009-11-11 Sanofi-Aventis Method for managing the risks associated with an increase in serum creatinine during dronedarone treatment
CN101869710A (zh) * 2009-04-24 2010-10-27 北京奥萨医药研究中心有限公司 降压药物组合物
US8602215B2 (en) 2010-06-30 2013-12-10 Sanofi Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation
US20140170158A1 (en) * 2012-12-17 2014-06-19 The Johns Hopkins University Compositions and methods for treating or preventing lung diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821232A (en) * 1990-05-11 1998-10-13 Pfizer Inc. Synergistic therapeutic compositions and methods
EP0629408A1 (en) * 1993-06-16 1994-12-21 LABORATOIRES MERCK, SHARP & DOHME-CHIBRET Combination of angiotensin converting enzyme inhibitors and AII antagonists
TR199701121T1 (xx) * 1995-04-07 1998-03-21 Novartis Ag Benazepril veya benazeprilat ve valsartan i�eren kombinasyon bile�imleri.
AU716519B2 (en) * 1995-06-30 2000-02-24 Laboratoires Merck Sharp & Dohme - Chibret Snc Method of treating renal disease using an ace inhibitor and an A II antagonist
CA2257946A1 (en) * 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
US6465502B1 (en) * 1998-12-23 2002-10-15 Novartis Ag Additional therapeutic use
PL353199A1 (en) * 1999-08-30 2003-11-03 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Also Published As

Publication number Publication date
IL153937A0 (en) 2003-07-31
CN1447691A (zh) 2003-10-08
AU9546501A (en) 2002-03-04
AU2001295465B2 (en) 2007-12-13
CZ2003534A3 (cs) 2003-06-18
EP1313468A2 (en) 2003-05-28
BG107558A (bg) 2004-01-30
NO20030761L (no) 2003-02-18
WO2002015891A2 (en) 2002-02-28
SK2062003A3 (en) 2003-08-05
GB0020691D0 (en) 2000-10-11
NO20030761D0 (no) 2003-02-18
WO2002015891A3 (en) 2002-06-13
DE10108215A1 (de) 2002-08-22
CA2372785A1 (en) 2003-08-21
US20030171415A1 (en) 2003-09-11
CA2415788A1 (en) 2002-02-28
JP2003238444A (ja) 2003-08-27

Similar Documents

Publication Publication Date Title
BR0113321A (pt) Combinação farmacêutica de antagonistas de angiotensina ii e inibidores da enzima conversora de angiotensina i
BR0211274A (pt) Combinação de um antagonista de receptor de aldosterona e um inibidor de hmg co-a redutase
BR9611362A (pt) Composicões detergentes
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
MEP6208A (en) The combination of a serotonin reuptake inhibitor and a 5-ht¿2c? antagonist, inverse agonist or partial agonist
BR0016166A (pt) Compostos de diidropirimidina heterocìclicos
MY138289A (en) Pharmaceutical compositions
ES2188214T3 (es) Composicion antioxidante que comprende acetil l-carnitina y acido alfa-lipoico.
AR002007A1 (es) UNA COMPOSICION TERAPEUTICA DE APLICACION TOPICA QUE CONTIENE UN ANTAGONISTA DE SUSTANCIA P Y UTILIZACION DE DICHO ANTAGONISTA PARA LAPREPARACIóN DE DICHA COMPOSICION PARA DISMINUIR Y/O ELIMINAR UN EFECTO SECUNDARIO IRRITANTE DE UN PRODUCTO CONTENIDO EN LA MISMA.
MX9308199A (es) Inhibidores de enzima.
BR9804352A (pt) Composição e processo para controlar o crescimento microbiológico.
KR940001900A (ko) 환상 유착 억제제
PT1135153E (pt) Utilizacoes para antagonistas e agonistas de receptores eph para tratar desordens vasculares
BR0007595A (pt) 4-(heterociclisulfonamido)-5-metóxi-6-(2-metoxifenó xi)-2-fenil-ou piridilpirimidinas como antagonistas de receptor de endotelina
BR9810520A (pt) Inibidor do fator xa isolado ou em combinação com um anti-agregador plaquetário, contra a trambose arterial
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BR9916004A (pt) Inibidores de proteinase c de pró-colágeno
FR2771010B1 (fr) Utilisation d'une combinaison d'un inhibiteur de l'enzyme de conversion de l'angiotensine et d'un diuretique pour le traitement des desordres microcirculatoires
MY129668A (en) Use of cgrp antagonists and cgrp release inhibitors for combating menopausal hot flushes
BR0214810A (pt) Combinação de um inibidor de il-1/18 com um inibidor de tnf para o tratamento de inflamação
PT84823B (pt) Processo para a preparacao de novos derivados de imidazois 1-substituidos com accao inibidora da dopamina-beta-hidroxilase e de composicoes farmaceuticas que os contem
AR000357A1 (es) Utilización de un antagonista de sustancia p para la preparación de una composición farmacéutica de aplicación topica para tratar las manchas rojas cutaneas de origen neurogeno y especialmente la rosacea y el eritema pudico
BR9712283A (pt) Método para inibir as cinases de proteìnas ativadas por tensão
Sesti et al. Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemia
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A , 9A E 10 ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.